Influence of [ 18 F]FDG-PET/CT on Clinical Management Decisions in Breast Cancer Patients-A PET/CT Registry Study

There is a lack of evidence regarding the clinical impact of [ F]fluorodeoxyglucose positron emission tomography/computed tomography ([ F]FDG-PET/CT, hereinafter referred to as PET/CT), especially regarding management changes and their link to overall survival. We analyzed 52 PET/CTs in 47 stage I-I...

Full description

Saved in:
Bibliographic Details
Published inDiagnostics (Basel) Vol. 13; no. 14; p. 2420
Main Authors Werner, Sebastian, Sekler, Julia, Gückel, Brigitte, la Fougère, Christian, Nikolaou, Konstantin, Pfannenberg, Christina, Preibsch, Heike, Engler, Tobias, Olthof, Susann-Cathrin
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 20.07.2023
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:There is a lack of evidence regarding the clinical impact of [ F]fluorodeoxyglucose positron emission tomography/computed tomography ([ F]FDG-PET/CT, hereinafter referred to as PET/CT), especially regarding management changes and their link to overall survival. We analyzed 52 PET/CTs in 47 stage I-IV breast cancer patients, selected from a prospective oncological PET/CT registry. Indications for PET/CT were primary staging ( = 15), restaging ( = 17), and suspected recurrence ( = 20). PET/CT-induced management changes were categorized as major or minor. PET/CT-induced management changes in 41 of 52 scans (78.8%; 38 of 47 patients (80.9%)), of which major changes were suggested in 18 of 52 scans (34.6%, 17 of 47 patients, 36.2%). PET/CT downstaged 6 of 15 primary staging patients, excluding distant metastases. Major management changes were documented in 3 of 17 restaging exams. PET/CT ruled out clinically suspected recurrence in 6 of 20 cases and confirmed it in 11 of 20. In three cases, locoregional recurrence had already been diagnosed via biopsy. In 30 of 52 exams, additional diagnostic tests were avoided, of which 13 were invasive. PET/CT-based management changes resulted in a 5-year survival rate of 72.3% for the whole study group, 93.3% for the staging group, 53.8% for the restaging group, and 68.4% for the recurrence group. This study shows that PET/CT significantly impacts clinical management decisions in breast cancer patients in different clinical scenarios, potentially determining the patient's tumor stage as the basis for further therapy more reliably and by avoiding unnecessary diagnostic tests.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics13142420